SEARCH:   Advanced

Blood, 1 July 2004, Vol. 104, No. 1, pp. 224-226. Prepublished online as a Blood First Edition Paper on March 18, 2004; DOI 10.1182/blood-2003-07-2461. This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 2003-07-2461v1 104/1/224    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Oosten, L. E. M. Articles by Goulmy, E. Search for Related Content PubMed PubMed Citation Articles by Oosten, L. E. M. Articles by Goulmy, E. Related Collections Immunotherapy Brief Reports Immunobiology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Brief report Artificial antigen-presenting constructs efficiently stimulate minor histocompatibility antigen–specific cytotoxic T lymphocytes Liesbeth E. M. Oosten, Els Blokland, Astrid G. S. van Halteren, Julie Curtsinger, Matthew F. Mescher, J. H. Frederik Falkenburg, Tuna Mutis, and Els Goulmy From the Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands; Center of Immunology, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis; and Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands. Cytotoxic T lymphocytes (CTLs) specific for hematopoietic-restricted minor histocompatibility antigens (mHags) are important reagents for adoptive immunotherapy of relapsed leukemia after allogeneic stem cell transplantation. However, expansion of these CTLs to therapeutic numbers is often hampered by the limited supply of antigen-presenting cells (APCs). Therefore, we evaluated whether cell-sized latex beads coated with HLA/mHag complexes HLA-A2/HA-1 or HLA-A2/HA-2 and recombinant CD80 and CD54 molecules can replace professional APCs. The artificial antigen-presenting constructs (aAPCs) effectively stimulated HA-1– and HA-2–specific CTL clones as shown by ligand-specific expansion, cytokine production, and maintenance of cytotoxic activity, without alteration of CTL phenotype. Furthermore, HA-1–specific polyclonal CTL lines were enriched as efficiently by aAPCs as by autologous HA-1 peptide-pulsed dendritic cells. Thus, aAPCs coated with HLA/mHag complexes, CD80, and CD54 may serve as tools for in vitro enrichment of immunotherapeutic mHag-specific CTL lines. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. M. E. Whitelegg, L. E. M. Oosten, S. Jordan, M. Kester, A. G. S. van Halteren, J. A. Madrigal, E. Goulmy, and L. D. Barber Investigation of Peptide Involvement in T Cell Allorecognition Using Recombinant HLA Class I Multimers J. Immunol., August 1, 2005; 175(3): 1706 - 1714. [Abstract] [Full Text] [PDF] K. Schilbach, G. Kerst, S. Walter, M. Eyrich, D. Wernet, R. Handgretinger, W. Xie, H.-G. Rammensee, I. Muller, H.-J. Buhring, et al. Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction Blood, July 1, 2005; 106(1): 144 - 149. [Abstract] [Full Text] [PDF] M. Kami, A. Makimoto, Y. Heike, and Y. Takaue Reduced-intensity Hematopoietic Stem Cell Transplantation (RIST) for Solid Malignancies Jpn. J. Clin. Oncol., December 1, 2004; 34(12): 707 - 716. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020